Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932186 | 0.92 | KCNH2 (0.46) | ITGB3ITGA2BFFAR1KCNH2 | |
| SCHEMBL910747 | 0.84 | KCNH2 (0.58) | CA1CA2ITGB3ITGA2BFFAR1 | |
| Trifluoroacetic Acid SCHEMBL911342 | 0.81 | CA12 (0.45) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL11932191 | 0.81 | LMNA (0.51) | — | |
| Trifluoroacetic Acid SCHEMBL4277212 | 0.79 | ALOX5 (0.46) | FFAR1 | |
| Trifluoroacetic Acid SCHEMBL911345 | 0.76 | CA12 (0.47) | CA12CA1CA2CA9ITGB3 | |
| Trifluoroacetic Acid SCHEMBL2164745 | 0.76 | CA12 (0.63) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL910120 | 0.74 | CA1 (0.54) | CA12CA1CA2CA9ITGB3 | |
| Trifluoroacetic Acid SCHEMBL9936935 | 0.73 | CA12 (0.59) | CA12CA1CA2CA9ITGB3 | |
| SCHEMBL873480 | 0.73 | CYP1A2 (0.57) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1922073-B1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1922073-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007018640-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.